Prospective comparative switch study from timolol 0.5% and latanoprost 0.005% to bimatoprost 0.03%

Advances in Therapy

Volumn 23, Issue 1, 2006, Pages 68-73

  Brittain, Christopher J ^a,b   Saxena, Rohit ^a   Waldock, Andrew ^a  

^a BEDFORD HOSPITAL NHS TRUST   (United Kingdom)

^b Beaufort Mansions   (United Kingdom)

Author keywords

Bimatoprost; Combination therapy; Glaucoma; Latanoprost; Timolol

Indexed keywords

BIMATOPROST; LATANOPROST; TIMOLOL;

ARTICLE; BLURRED VISION; CARDIOPULMONARY FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SUBSTITUTION; DYSPNEA; ERYTHEMA; FORCED EXPIRATORY VOLUME; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; PEAK EXPIRATORY FLOW; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY;

ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA; HEART RATE; HUMANS; HYPEREMIA; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; RESPIRATORY FUNCTION TESTS; TIMOLOL;

EID: 33646144192     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850348     Document Type: Article

References (12)

1. Gibson JM, Rosenthal AR, Lavery J. A study of the prevalence of eye disease in the elderly in an English community. Trans Ophthalmol Soc UK. 1985;104:192-203.
2. AGIS Investigators. The Advanced Glaucoma Interventional Study (AGIS) 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
3. Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91:1361-1363.
4. Diggory P, Cassels-Brown A, Vail A, Abbey L, Hillman J. Avoiding unsuspected respiratory side-effects of topical timolol by using cardioselective or sympathomimetic agents. Lancet. 1995;345:1604-1606.
5. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol. 2000;84:710-713.
6. Aim A, Stjernschantz J, Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology. 1995;102:1743-1752.
7. Camras CB, US Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
8. Watson P, Stjernschantz J, Scandinavian Latanoprost Study Group. A six-month, randomized, double masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137.
9. Diestelhorst M, Larsson L-I, European Latanoprost Fixed Combination Study Group. A 12-week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88:199-203.
10. Brandt J, VanDenburgh A, Chen K, Whitcup S, for the Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108:1023-1031.
11. Sherwood M, Brandt J, for the Bimatoprost Study Groups 1 + 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated IOP. Surv Ophthalmol. 2001;45(suppl 4):S361-S368.
12. Noecker R, Dirks M, Choplin N, Bernstein P, Batoosingh A, Whitcup S. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.